<DOC>
	<DOCNO>NCT01337674</DOCNO>
	<brief_summary>This study evaluate safety tolerability MK-4618 coadministered antihypertensive agent evaluate change blood pressure follow co-administration MK-4618 beta blocker vasodilator . The primary hypothesis study MK-4618 result clinically meaningful change systolic blood pressure relative placebo co-administered beta-blocker amlodipine .</brief_summary>
	<brief_title>Co-Administration MK-4618 With Antihypertensive Agents ( MK-4618-010 )</brief_title>
	<detailed_description />
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male female childbearing potential Not nurse mother Must stable dose beta blocker ( Panel A ) amlodipine ( Panel B ) treatment hypertension least 6 week prior enrollment . Must take designated daily dose metoprolol amlodipine duration study In good health hypertension Nonsmoker Participant rest systolic blood pressure &lt; 150 &gt; 95 mmHg diastolic blood pressure &lt; 95 &gt; 75 mmHg prestudy clinical evaluation Any illness might confound result study pose risk participation History orthostatic hypotension ( decrease blood pressure upon stand accompany symptom lightheadedness dizziness ) History cancer , except certain skin cervical cancer cancer treat successfully 10 year prior screen Condition warning , contraindication , precaution use extend release metoprolol ( Panel A ) amlodipine ( Panel B ) Consumes excessive amount alcohol caffeine daily Has multiple and/or severe allergy ( include latex allergy ) anaphylactic reaction significant intolerance drug food Uses illicit drug history drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>